These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27020103)

  • 1. Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.
    Jiang Y; Verbiest T; Devery AM; Bokobza SM; Weber AM; Leszczynska KB; Hammond EM; Ryan AJ
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):772-81. PubMed ID: 27020103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
    Senra JM; Telfer BA; Cherry KE; McCrudden CM; Hirst DG; O'Connor MJ; Wedge SR; Stratford IJ
    Mol Cancer Ther; 2011 Oct; 10(10):1949-58. PubMed ID: 21825006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
    Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
    Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
    Wang W; Duan B; Zeng L
    Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells.
    Zhan L; Qin Q; Lu J; Liu J; Zhu H; Yang X; Zhang C; Xu L; Liu Z; Cai J; Ma J; Dai S; Tao G; Cheng H; Sun X
    Dis Esophagus; 2016 Apr; 29(3):215-23. PubMed ID: 25604309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib nanoparticles potentiated radiosensitization effects on lung cancer.
    Wu M; Liu J; Hu C; Li D; Yang J; Wu Z; Yang L; Chen Y; Fu S; Wu J
    Int J Nanomedicine; 2018; 13():8461-8472. PubMed ID: 30587971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
    Karnak D; Engelke CG; Parsels LA; Kausar T; Wei D; Robertson JR; Marsh KB; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
    Clin Cancer Res; 2014 Oct; 20(19):5085-96. PubMed ID: 25117293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
    Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
    Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
    Mao Y; Huang X; Shuang Z; Lin G; Wang J; Duan F; Chen J; Li S
    Cancer Med; 2018 Apr; 7(4):1285-1296. PubMed ID: 29479816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
    Liu Q; Gheorghiu L; Drumm M; Clayman R; Eidelman A; Wszolek MF; Olumi A; Feldman A; Wang M; Marcar L; Citrin DE; Wu CL; Benes CH; Efstathiou JA; Willers H
    Oncogene; 2018 May; 37(21):2793-2805. PubMed ID: 29511347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of olaparib and camptothecin for effective radiosensitization.
    Miura K; Sakata K; Someya M; Matsumoto Y; Matsumoto H; Takahashi A; Hareyama M
    Radiat Oncol; 2012 Apr; 7():62. PubMed ID: 22524618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
    Miyasaka A; Oda K; Ikeda Y; Wada-Hiraike O; Kashiyama T; Enomoto A; Hosoya N; Koso T; Fukuda T; Inaba K; Sone K; Uehara Y; Kurikawa R; Nagasaka K; Matsumoto Y; Arimoto T; Nakagawa S; Kuramoto H; Miyagawa K; Yano T; Kawana K; Osuga Y; Fujii T
    BMC Cancer; 2014 Mar; 14():179. PubMed ID: 24625059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
    Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
    BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors.
    Wang T; Kyle AH; Baker JHE; Liu NA; Banáth JP; Teymori S; Minchinton AI
    DNA Repair (Amst); 2024 Jul; 139():103689. PubMed ID: 38749239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation.
    Kageyama SI; Junyan D; Hojo H; Motegi A; Nakamura M; Tsuchihara K; Akimoto T
    J Radiat Res; 2020 Mar; 61(2):177-186. PubMed ID: 31976528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.
    Verhagen CV; de Haan R; Hageman F; Oostendorp TP; Carli AL; O'Connor MJ; Jonkers J; Verheij M; van den Brekel MW; Vens C
    Radiother Oncol; 2015 Sep; 116(3):358-65. PubMed ID: 25981132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.